替沙来塞仑与复发/难治性弥漫性大B细胞淋巴瘤历史治疗的间接比较
本研究无头对头试验,采用倾向评分加权间接比较替沙来塞仑(JULIET研究)与CORAL研究随访人群的历史治疗。在FAS和ITT人群中,替沙来塞仑均与较低的死亡风险和较高的总缓解率相关。
要点
- FAS人群中替沙来塞仑较历史治疗降低死亡风险,调整HR为0.44(95%CI 0.32-0.59)。
- ITT人群中替沙来塞仑较历史治疗降低死亡风险,调整HR为0.60(FSW)和0.57(SMRW)。
- FAS人群中替沙来塞仑较历史治疗提高总缓解率,调整率差为36%(95%CI 22%-0.48%)。
核心结论
- 该分析支持复发/难治性弥漫性大B细胞淋巴瘤患者接受替沙来塞仑治疗较其他历史治疗可获得改善的缓解和总生存。
研究设计与样本
- 无头对头试验,采用倾向评分加权(SMRW和FSW)间接比较替沙来塞仑(JULIET研究)与CORAL研究随访人群的历史治疗。
- 分别比较JULIET FAS与CORAL随访FAS、JULIET ITT与CORAL随访ITT人群,调整基线混杂因素。
主要发现
- FAS人群调整HR(FSW和SMRW)均为0.44(95%CI 0.32-0.59),P<.001。
- ITT人群调整HR:FSW为0.60(95%CI 0.44-0.77),SMRW为0.57(95%CI 0.44-0.73),均P<.001。
- FAS人群中位OS:替沙来塞仑12.48个月 vs CORAL 4.34至4.40个月。
- ITT人群中位OS:替沙来塞仑8.25个月 vs CORAL 4.04至4.86个月。
- FAS人群调整缓解率差(FSW和SMRW)均为36%(95%CI 22%-0.48%),P<.001;ITT人群SMRW调整后为11%(95%CI 0%-22%),P=.043。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
No head-to-head trials have compared the efficacy of tisagenlecleucel vs historical treatments for adults with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). This study indirectly compared the overall survival (OS) and overall response rate (ORR) associated with tisagenlecleucel, using data from the JULIET study (Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients; #NCT02445248), vs historical treatments assessed in the CORAL (Collaborative Trial in Relapsed Aggressive Lymphoma) study follow-up population. To assess treatment effects in the treated (full analysis set [FAS]) and enrolled (intention-to-treat [ITT]) study populations, the JULIET FAS vs the CORAL follow-up FAS and JULIET ITT vs CORAL follow-up ITT populations were separately compared. Propensity score weighting using standardized mortality ratio weight (SMRW) and fine stratification weight (FSW) was used to compare OS and ORR, adjusting for baseline confounders. The results indicated that tisagenlecleucel was associated with a lower hazard of death among the FAS (adjusted hazard ratio [95% confidence interval], both FSW and SMRW, 0.44 [0.32, 0.59]) and ITT populations (FSW, 0.60 [0.44, 0.77]; SMRW, 0.57 [0.44, 0.73]; all, P < .001). Median OS was 12.48 months (JULIET) vs 4.34 to 4.40 months (CORAL) for the FAS, and 8.25 (JULIET) months vs 4.04 to 4.86 (CORAL) months for the ITT populations. Tisagenlecleucel was associated with a significantly higher ORR compared with historical treatments among the FAS (adjusted response rate difference [95% confidence interval], both FSW and SMRW, 36% [22%, 0.48%]; P < .001) and among the ITT populations after SMRW adjustment (11% [0%, 22%]; P = .043). This analysis supports that improved response and OS are achieved in patients with r/r DLBCL treated with tisagenlecleucel compared with those treated with alternative historical treatments.
引用
- Maziarz RT, Zhang J, Yang H, et al. Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2022. PMID: 35030634. doi:10.1182/bloodadvances.2021006280
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。